Therefore, CD90 acts not only as a valuable biomarker for evaluating ADSC potentials or monitoring metabolic status of WAT, but also as a potential target for treating obesity-associated metabolic disorders. This evidence concerns the gene THY1 and obesity due to melanocortin 4 receptor deficiency.